Roth Capital Reiterates Buy On Pharmacyclics Shares, $185 PT
In a research report issued today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Pharmacyclics (NASDAQ:PCYC) with a price target of $185.00.
Pantginis noted, “Following the recent announcement of a combination study of Imbruvica with Bristol Myers Squibb’s (BMY-NC) anti-PD1 Opvido, PCYC announced another combination study, this time with Roche’s (ROG-NC) anti-CD20 antibody Gazyva. We believe this is just the start of combination studies to come for Imbruvica, which has an impressive safety profile, making it an ideal combination therapy.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joseph Pantginis has a total average return of -11.9% and a 33.1% success rate. Pantginis has a -1.5% average return when recommending PCYC, and is ranked #3327 out of 3337 analysts.